Word

SEPTERNA

Status

Pending

Status Code

730

Status Date

Monday, December 18, 2023

Serial Number

97148591

Mark Type

4000

Filing Date

Tuesday, November 30, 2021

Published for Opposition

Tuesday, April 25, 2023

Trademark Owner History

Septerna, Inc. - Owner At Publication

Classifications

40 Custom manufacture of biochemical systems, namely, custom manufacture of systems for targeting G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; custom manufacturing for others, namely, manufacturing of pharmaceutical preparations for the treatment of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders

5 Pharmaceutical preparations for modulating G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; pharmaceutical preparations for use in neurology, endocrinology, metabolism, immunology, oncology, cardiovascular medicine, gastroenterology, pain, anesthesiology, dermatology, ophthalmology, psychiatry, pulmonology, urology, reproductive medicine, and orthopedics; pharmaceutical preparations and substances that are used alone or in combination with other pharmaceuticals, preparations or substances, and that act on various GPCRs, GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; chemical and biochemical preparations and substances for medical purposes for treatment and/or diagnosis of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders; pharmaceutical preparations for targeting GPCRs, GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; biological preparations for the treatment of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders; Biochemical and chemical reagents for testing and characterizing G protein-coupled receptors (GPCRs), for use in medical research

1 Biochemical and chemical reagents for testing and characterizing G protein-coupled receptors (GPCRs), for scientific research use; chemical reagents for use in genetic research

44 Providing a website featuring information about the treatment and/or diagnosis of neurological disorders, endocrine disorders, metabolic disorders, autoimmune diseases and immunological disorders, cancer, cardiovascular disorders, gastrointestinal disorders, pain, ophthalmic disorders, psychiatric disorders, respiratory disorders, urologic and reproductive disorders, and musculoskeletal disorders

42 Bio-technology and scientific services, namely, research, and production and development services relating to bio-technology and science, namely, G-protein coupled receptors (GPCRs), GPCR ligands, GPCR transducer proteins, and GPCR interacting proteins; pharmaceutical research and development; Scientific and technological services, namely, biological and bio-technology analysis services; scientific and medical laboratory services; biochemistry research services, namely, treating therapeutic targets through chemical and biochemical preparations

Trademark Events

Feb 16, 2024

Teas Change Of Correspondence Received

Feb 16, 2024

Attorney/Dom.Rep.Revoked And/Or Appointed

Feb 16, 2024

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Dec 20, 2023

Notice Of Approval Of Extension Request E-Mailed

Dec 18, 2023

Sou Extension 1 Granted

Dec 18, 2023

Sou Extension 1 Filed

Dec 18, 2023

Sou Teas Extension Received

Jun 20, 2023

Noa E-Mailed - Sou Required From Applicant

Apr 25, 2023

Official Gazette Publication Confirmation E-Mailed

Apr 25, 2023

Published For Opposition

Apr 5, 2023

Notification Of Notice Of Publication E-Mailed

Mar 22, 2023

Approved For Pub - Principal Register

Mar 15, 2023

Teas/Email Correspondence Entered

Mar 13, 2023

Correspondence Received In Law Office

Mar 13, 2023

Teas Response To Office Action Received

Sep 13, 2022

Notification Of Non-Final Action E-Mailed

Sep 13, 2022

Non-Final Action E-Mailed

Sep 13, 2022

Non-Final Action Written

Sep 9, 2022

Assigned To Examiner

Dec 3, 2021

New Application Office Supplied Data Entered

Dec 3, 2021

New Application Entered